© BioMara
BioMara extracts high-quality fucoidan from brown seaweed using a unique process that is designed to maximise the value of seaweed by isolating multiple healthy products from the same biomass. This approach reduces waste and enhances scalability, aligning with industry demands for efficient and price-competitive seaweed ingredient production, potentially benefiting the entire value-chain of this nascent industry.
“This funding comes at a pivotal time as we build relationships with customers who are eager to incorporate our Seafibrex high-fibre ingredient as well as our Thalivra and Revyntra fucoidan extracts into their products,” said Jay Dignan, CEO of BioMara, in a press release.
“Our focus now is on building momentum: expanding production and increasing sales, which will underpin the product’s success in the food and wellness markets.”
Fucoidan is increasingly recognised for its health-promoting properties, including immune support, gut health benefits and anti-inflammatory effects. Unlike traditional seaweed processing methods, BioMara says that its proprietary technology retains fucoidan bioactivity and unlocks multiple valuable compounds from the same biomass, minimising waste and maximising yield.
In addition to enhancing production, Dignan says that the investment will also support building clinical evidence for the benefits of BioMara’s products. The company is working with independent third party laboratory facilities to further substantiate the health benefits of its fucoidan, strengthening customer confidence and addressing new sectors and markets. This will help BioMara build sales traction by collaborating with food and wellness brands that prioritise the use of natural and functional ingredients.
Since its launch, BioMara has raised over £520,000 in private funding and secured more than £600,000 in non-dilutive grant funding through competitive research and innovation programmes.
